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Defective HNF4alpha-dependent gene expression
as a driver of hepatocellular failure in alcoholic
hepatitis
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Alcoholic hepatitis (AH) is a life-threatening condition characterized by profound hepato-
cellular dysfunction for which targeted treatments are urgently needed. Identification of
molecular drivers is hampered by the lack of suitable animal models. By performing RNA
sequencing in livers from patients with different phenotypes of alcohol-related liver disease
(ALD), we show that development of AH is characterized by defective activity of liver-
enriched transcription factors (LETFs). TGFβ1 is a key upstream transcriptome regulator in
AH and induces the use of HNF4α P2 promoter in hepatocytes, which results in defective
metabolic and synthetic functions. Gene polymorphisms in LETFs including HNF4α are not
associated with the development of AH. In contrast, epigenetic studies show that AH livers
have profound changes in DNA methylation state and chromatin remodeling, affecting
HNF4α-dependent gene expression. We conclude that targeting TGFβ1 and epigenetic drivers
that modulate HNF4α-dependent gene expression could be beneficial to improve hepato-
cellular function in patients with AH.
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Liver-related mortality has increased in the last decade, par-tially due to the higher incidence of addictions in the form ofalcohol-related cirrhosis1–3. The prognosis of ALD depends
on the development of liver failure, mainly in the form of AH4.
The burden of AH has increased in many countries and repre-
sents an important public health problem2,5. The genetic and
epigenetic factors involved in the development of AH in heavy
drinkers are not well known6. GWAS studies have shown that
variations in PNPLA3,MBOAT7, and TM6SF2 loci confer risk for
alcohol-related cirrhosis7, but the association of specific loci with
AH is unknown. Because alcohol abuse has been associated with
DNA methylation changes in humans8,9 and epigenetic dysre-
gulation in experimental liver injury10,11, it is conceivable that
epigenetic factors play a role in AH. Liver failure in the setting of
AH was traditionally considered to be secondary to a flare in
intrahepatic inflammation12. Consequently, therapies have been
directed towards decreasing inflammatory mediators (i.e. pre-
dnisolone), with limited efficacy13. We recently showed that
bilirubinostasis, inefficient regeneration of hepatocytes and a
compensatory ductular reaction may play a pathogenic role in
AH14–17. However, the mechanisms of liver failure in the setting
of AH remain obscure. This human-based translational study
combined integrated multi-OMICs from a large cohort of human
samples along with in vitro and experimental animal models with
a goal to address this knowledge gap (see “Data Analysis
Workflow” in Supplementary Fig 1). In the present work, we
describe that livers from patients with AH undergo profound
transcriptomic reprogramming, with downregulation of HNF4α
and other LETFs. We detect the expression of a fetal isoform of
HNF4α in these patients and describe the epigenetic landscape of
HNF4a dependent transcriptome. We propose TGFβ1-mediated
HNF4α de-regulation and the epigenetic changes in HNF4α-
depending genes as potential new therapeutic avenues to treat this
lethal disease.
Results and discussion
Patients with AH undergo deep transcriptional reprogram-
ming. In order to uncover the mechanisms involved in progres-
sion to AH in patients with ALD, we first performed a
comprehensive analysis of liver RNA sequencing (RNA-seq) data
from a large series of patients (N= 92) with different disease
stages including normal liver (Normal, N= 10), early alcoholic
steatohepatitis (ASH, N= 12), AH with liver failure (AH, N= 18)
and a unique set of explants from patients with AH that under-
went urgent liver transplantation (exAH, N= 10)13 (Fig. 1a). As
diseased controls, we included patients with non-alcoholic fatty
liver disease (NAFLD, N= 9), chronic hepatitis C (HCV, N= 9)
and compensated HCV cirrhosis (CIRR, N= 9). The principal
component analysis (PCA) showed patient clustering according
to the progressive clinical phenotypes (Fig. 1b). Thus, while early
ASH clustered along with chronic hepatitis C and NAFLD close
to normal livers, patients with AH showed a much more
deregulated transcriptome. We then performed a comparative
analysis between normal livers and different ALD phenotypes.
As shown in Fig. 1c, analytical parameters of liver injury (i.e.
AST) and hepatocellular synthetic function (i.e. INR, serum
bilirubin and albumin) as well as clinical scoring systems (i.e.
Child-Pugh and MELD) were markedly impaired after the onset
of AH (Supplementary Table 1). Unbiased clustering and Short
Time Expression Miner (STEM) algorithm identified 13 profiles
of gene expression across the 4 selected disease stages (Fig. 1d,
Supplementary Fig. 2a–d and Supplementary Data 1). These
profiles were grouped into 4 main patterns along ALD progres-
sion including compensatory transient gene expression changes
in early stages, genes progressively up or down-regulated along
disease progression or genes up or down-regulated only after the
onset of liver failure (Fig. 1e). Top upstream regulators and target
genes belonging to these 4 patterns are depicted in Fig. 1f. A
detailed gene set enrichment analysis revealed down-regulation of
genes related to basic hepatocyte functions (i.e. metabolism of
amino acids and lipids, biological oxidations, mitochondrial
function and bile acid metabolism), while cell proliferation,
extracellular matrix regulation and inflammation related path-
ways were enriched among up-regulated genes (Supplementary
Fig. 3). Overall, these changes could explain key features in AH
including massive fibrosis, proliferation of immature ductular
cells and bilirubinostasis14,15. In order to gain insight into the
main drivers of gene expression that could result in the devel-
opment of hepatocellular failure in AH, we analyzed the predicted
activity of transcription factors using a complementary approach,
by combining the search of transcription factor binding motifs in
the promoter of differentially expressed genes (DEG) and by the
use of Ingenuity Pathway Analysis (IPA) software to uncover
predicted upstream transcription factor activity (see Material and
Methods section). Early compensated state of ALD was char-
acterized by an increased predicted activity of the hepatoprotec-
tive transcription factor PPARγ (Fig. 2a). In contrast,
development of AH was associated with a profound decrease in
the activity of LETFs, especially HNF4α (Fig. 2b, Supplementary
Data 2). To illustrate the transcription factor footprint in Early
ASH and in AH, a set of PPARγ and HNF4α target genes are
shown in Fig. 2c, d.
The results obtained in human livers were assessed in several
animal models of early and advanced ALD using the same
approach to infer transcription factor activity from liver RNA
sequencing (Supplementary Fig. 4a). Mice subjected to early
experimental ALD (High Fat Diet -HFD- plus intragastric
Ethanol administration -EtOH- for 3 weeks) showed increased
liver damage and hepatocyte steatosis in the absence of significant
fibrosis (Supplementary Fig. 4b,c). In these mice, we found a
marked predicted activation of PPARγ resembling our analyses in
patients with early stages of ALD (Supplementary Fig. 4d). Mice
subjected to the model of severe ALD (CCl4 for 9 weeks and then
EtOH after a wash-up period) showed increased liver damage
(Supplementary Fig. 4b, c) and pericellular (“chicken-wire”)
fibrosis similar to the findings that we described in humans
(Supplementary Fig. 4d, e)14 but without the parameters of liver
failure (i.e. jaundice, coagulopathy). The transcription factor
predicted activity analysis was characterized by decreased FOXA-
1, but not HNF4α (Supplementary Fig. 4f). Interestingly, while
the expression of some HNF4α target genes was decreased in
these mice (i.e. PCK1), other well described targets were increased
(i.e. coagulation factor VII F7) (Supplementary Fig. 4g). The
relatively preserved HNF4α-dependent gene expression could
partially explain why these mice do not develop liver failure. It is
therefore plausible that manipulating HNF4α could favor the
development of alcohol-induced liver failure in these mice. These
results could be beneficial in developing a useful preclinical model
of true AH. The fact that HNF4α is still active in these mice could
also be partially due to defective TCF3/4 repression activity over
HNF4α18.
Fetal P2-dependent HNF4α isoforms are increased in AH.
Because HNF4α was the most inhibited LETF found in our
analysis of human AH, we decided to focus on its potential role in
mediating liver failure in AH. HNF4α is responsible for the
transcription activation of mature hepatocyte specific genes19–23
and it is able to reverse established liver cirrhosis24, suggesting a
role in preserving hepatocellular homeostasis during chronic liver
injury25. We studied the correlation between parameters
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indicative of liver synthetic function and HNF4α activity. As
shown in Fig. 3a, development of liver failure in the setting of AH,
as indicated by elevated serum bilirubin levels and INR and
decreased albumin synthesis, was strongly associated with a
negative HNF4α Z-Score on IPA analysis. HNF4α is known to
have two types of isoforms: the adult isoform is expressed in the
liver during adulthood (HNF4α-P1) while the fetal isoform is
driven by a ~45 kb upstream alternative promoter (HNF4α-P2).
During embryonic development, the P2 promoter is used and an
alternative splicing of the first exon is produced, originating the
fetal isoforms α7–12. These variants lack the AF-1 domain in the
N-terminal of the protein resulting in less transactivation activity,
affecting its interaction with coregulators (Fig. 3b)26–28. The
relevance of P2 derived isoforms in adult human liver disease is
not well-known. We then studied the expression of N-terminal
isoforms in normal and AH human livers. HNF4α-P1 mRNA
remained unchanged in AH, while there was a dramatic up-
regulation in the expression of the fetal HNF4α-P2 isoform in
livers from patients with AH (Fig. 3c). We found that the
expression of the lncRNA HNF4A-AS1, which shares the P1
promoter region with HNF4A, was downregulated in patients
with AH (Fig. 3c). The function of this antisense lncRNA is
unknown. The expression of HNF4A-AS1 measured by real time
PCR was higher in human primary hepatocytes than in HepG2
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and Hep3B cell lines (mean of 33 vs 37 and 38 cycles, respec-
tively). The expression of this lncRNA could be related to HNF4α
regulation and cell differentiation. Further studies should evaluate
the functional role of this lncRNA in hepatocyte function and, in
particular, in patients with AH. Importantly, up-regulation of
HNF4α-P2 was not seen in early forms of ALD or in other types
of liver diseases such as NAFLD and chronic hepatitis C (Fig. 3c).
In order to further explore the regulation of the HNF4α locus, we
used a specific computational tool (i.e. Multivariate Analysis of
Transcript Splicing -MATS-)29 to assess differences in HNF4α
Fig. 1 Liver transcriptome encompasses disease progression in patients with ALD. a Human phenotypes included in the RNA-seq analysis: normal human
livers (n= 10), early ASH (n= 12), AH (n= 18) and explants from AH patients (n= 11). Diseased controls: liver biopsies from patients with NAFLD (n= 9),
non-cirrhotic HCV (n= 9) and compensated cirrhosis (n= 9). Unbiased clustering and Short Time Expression Miner (STEM) algorithm were used to group
patients by RNA profiling and to identify main time-correlated patterns of expression. Kendall rank correlation coefficient and differential expression
analysis (limma) between “Normal” and “Early ASH” and between “Early ASH” and “AH” groups was performed. Motif enrichment analysis (Opossum) and
network analysis (Ingenuity Pathway Analysis) were used to identify main transcription factors involved in gene expression changes. b A schematic
summary of Principal component analysis (PCA). c Heatmap of clinical and laboratory data of ALD patients: (Top) liver function tests: albumin serum
levels, International Normalized Ratio (INR), aspartate aminotransferase (AST) and total serum bilirubin levels; (Bottom) Liver prognostic scores including
Child-Pugh, MELD and ABIC; The color scale on the right indicates the range of each laboratory or clinical parameter. d Heatmap of STEM results, showing
average expression (normalized log counts) of main groups of genes based on gene enrichment profile expression. Left column: STEM profile and number
of genes. On top, patient phenotypes. Right panel, hierarchical clustering of profiles. See Supplementary Fig 2 for additional data from STEM analysis.
e Heatmap of STEM results showing mean counts for all pattern-grouped genes for patients belonging to each disease stage. In the right panel, schematic
representation (thick arrows) of main time-related expression patterns. f IPA analysis showing upstream regulators and soluble factors for each of four
general expression pattern clusters. Regulators identified as cytokines, growth factors and receptors with a threshold ZS of 2 are presented (top-middle).
Among the most 100 differentially expressed genes for each analysis, genes encoding secreted proteins are presented (bottom)
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splicing between normal and AH livers. AH livers showed
increased expression of exon 1D, 4, 5, 6, 9, and 10 (Supplemen-
tary Fig. 5a, b). The correlation of the expression of exon 1D with
any of the other 10 exons was higher in patients with AH
(Supplementary Fig. 5c–e). These differences suggest a profound
deregulation of HNF4A gene splicing. The analysis of the exon
exclusion events also showed an increase in the exclusion of exon
7 and a decrease of in exclusion of exon 8 (Supplementary
Fig. 5f). Exon 8 encodes for a fraction of the AF-2 domain, which
is essential for post-translational regulation and activity of
HNF4α30. Alterations of splicing in this region could thus affect
HNF4α stability and/or activity. Further studies should evaluate
the functional role of these C-terminal variants.
The hepatic expression of HNF4α isoforms in patients with AH
was then assessed by immunohistochemistry (IHC) with specific
N-terminal antibodies. HNF4α-P1 signal was detected in the
nuclei of both normal and AH hepatocytes. Conversely, the
HNF4α-P2 isoform, barely detected in the nucleus of normal
AH
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livers, was markedly up-regulated in AH hepatocytes (Fig. 2d, e).
Other important LETFs inhibited in AH such as HNF1α and
FOXA-1 showed decreased nuclear expression and increased
cytoplasmic localization (Supplementary Fig. 6a–c). In contrast,
RXRα, whose heterodimer with PPARγ was predicted to be
inhibited (Fig. 2b), did not show differences in the IHC of these
patients compared to normal livers (Supplementary Fig. 6d, e).
Knockdown of HNF4α-P2 ameliorates HNF4α-P1 expression.
We then sought to determine whether P2 expression in hepato-
cytes contributes to the loss of mature hepatocyte biological
functions during AH including bile acid homeostasis, as well as
metabolic and synthetic functions. To address this question, we
used a well-characterized model of hepatocyte de-differentiation
of HepaRG-tdHep into HepaRG cells31. HepaRG cells were first
differentiated into the hepatocyte lineage by a two-week treat-
ment with 2% DMSO. Then, these so-called tumor-derived
HepaRG hepatocyte-like cells (HepaRG-tdHep) were cultured in
the absence of DMSO and at low confluence. The expression of
HNF4α isoforms and HNF4α targets was analyzed at different
time points (Fig. 3f). Hepatocyte de-differentiation resulted in a
rapid decline of HNF4α-P1 isoform expression with a constant
upregulation of HNF4α-P2 isoforms (Fig. 3g). Hepatocyte-
specific genes such as PCK1 and F7 were downregulated
(Fig. 3h), while Vimentin (VIM), a known EMT marker, was
upregulated (Fig. 3i). In AH patients, we found increased
expression of progenitor cell markers and markers of epithelial-
to-mesenchymal transition (EMT), suggesting a de-differentiation
of hepatocytes (Supplementary Fig. 7a). This was also suggested
by a correlation analysis with published tissue and cell type
published gene sets (Supplementary Fig. 7b,c). We then per-
formed gain and loss-of function studies to elucidate the role of
P2 in hepatocyte biological functions. Overexpression of HNF4α-
P2 resulted in decreased expression of the HNF4α-target gene
PCK1 (Fig. 3j, k). In contrast, abrogation of HNF4α-P2 resulted
in increased HNF4α-P1 gene and protein expression (Fig. 3l–n).
The expression of HNF4α target genes involved in hepatocyte
metabolic, secretory and synthetic functions such as PCK1, F7,
Albumin (ALB), CYP7A1, CYP27A1 and biliary salt export pump
(BSEP) was also increased (Fig. 3o, p). Moreover, this maneuver
restored bile acid synthesis and the formation of glyco-cheno-
deoxycholate conjugated bile acid (Fig. 3q, Supplementary Fig. 8),
and also stimulated glucose production (Fig. 3r) in human pri-
mary hepatocytes. Overall, these results suggest that P2 over-
expression negatively regulates HNF4α-dependent gene
expression and several biological properties of mature hepato-
cytes that are commonly lost in AH.
TGFB1 mediates HNF4α dysregulation. We next explored the
potential mechanisms involved in HNF4α P1-P2 imbalance
during the development of liver failure in AH. Unbiased analysis
of transcriptomic changes in patients progressing to AH uncov-
ered potential main upstream regulators (Fig. 4a). Transforming
growth factor β1 (TGFβ1) was found to be the most relevant
factor, followed by epidermal growth factor (EGF). Expression of
TGFβ1 and its receptors 1 and 2, as well as the EGF receptor
ligand Amphiregulin (AREG), were markedly increased in AH
livers (Fig. 4b, c). We then hypothesized that TGFβ1 and AREG
regulate the relative expression of HNF4αP1-P2 in hepatocytes.
In HepG2 and in Hep3B cells, TGFβ1 and AREG synergistically
decreased HNF4α-P1 protein levels and RNA expression while
TGFβ1 but not AREG increased HNF4α-P2 levels and expression
(Fig. 5a, b, Supplementary Fig 9a, b, Hep3B experiments are
shown). HNF4α-P1 is known to inhibit the expression of HNF4α-
P232. Nevertheless, in our experiments HNF4α-P1 down-
regulation upon TGFβ1 treatment occurred several hours later
than HNF4α-P2 upregulation, indicating a direct action of TGFβ1
(Fig. 5a, Supplementary Fig. 9a, b). Accordingly, knockdown of
HNF4α-P1 expression did not increase HNF4α-P2 levels at
baseline or in the presence of TGFβ1 (Fig. 5c). The effect of
TGFβ1 was TGFβ1R1-dependent (Fig. 5d). Surprisingly, the
inhibition of the nuclear translocation of SMAD family proteins
by SMAD4 knockdown blocked TGFβ1-mediated HNF4α-P1
downregulation and transcriptional function but did not inhibit
HNF4α-P2 upregulation. These results suggest that the action of
TGFβ1 on HNF4α includes SMAD-dependent and SMAD-
independent signaling pathways (Fig. 5e). TGFβ1 activated
kinase 1 (TAK1) is essential for hepatocyte proliferative response
and survival33. Strikingly, the selective inhibition of TAK1
reduced TGFβ1-mediated induction of HNF4α-P2 expression
without affecting HNF4α-P1 downregulation (Fig. 5f). Cellular
Src (c-Src) selectively decreases HNF4α-P1 levels in response to
EGF34. But it can also be activated by TGFβ135 and transduce the
signal through TAK1 in the context of hepatocyte protection36.
The pharmacological inhibition of c-Src completely reverted the
effects of TGFβ1 on both HNF4α-P1 and HNF4α-P2, indicating
an essential role in HNF4α deregulation (Fig. 5g, h). One of the
multiple effectors of c-Src and TAK1 is AP-1 transcription factor.
We then scanned the genomic region around HNF4α-P2 Tran-
scription Start Site (TSS, ±1 kb) in search of AP-1 transcription
factor binding sites (TFBS). Only 6 FOS::JUN TFBS were found
with high Relative Score (>85%, Supplementary Fig 10a, b). Next,
we performed chromatin immunoprecipitation using RNA
Polymerase II (RNA Pol II) and phospho-c-JUN antibodies. We
studied several genomic regions. Interestingly, upon TGFβ1
Fig. 3 Fetal HNF4α-P2 isoform increase in patients with AH and its effect in HNF4α-P1. a Levels of bilirubin, INR and albumin levels in serum along ALD
progression (values expressed as Mean ±SEM) and HNF4α footprint Z-Score. b Scheme of HNF4A gene fetal (P2) and adult (P1) isoforms structure and
protein variants. c Real-Time quantitative PCR (qPCR) of HNF4A-P1 and P2 dependent isoforms, and lncRNA HNF4A-AS1 in the cohort of patients in Fig. 1.
d Immunohistochemical detection of adult and fetal HNF4A protein variants in patients with AH (n= 9), and controls (n= 9), using N-terminal specific
antibodies. e Semi-quantitative assessment of IHC signal for each antibody for nuclear staining. f–i HepaRG cells were retro-differentiated into tumor-
derived Hepatocyte-like cells (HepaRG-tdHep); de-differentiation was induced with FBS and RNA was extracted at 4, 24, and 48 h (n= 3 for each time
point); qPCR of g HNF4α-P1 and P2 isoforms, h phosphoenol-pyruvate carboxy-kinase (PCK1), clotting Factor VII (F7) and i vimentin (VIM) j, k HepG2 cells
were transfected with plasmids encoding P1 (HNF4α2) and P2 (HNF4α8) variants. P1 was maintained at same dose while P2 was increased as indicated.
RNA was extracted 12 h and 24 h after transfection (n= 3); qPCR of j HNF4α-P2 isoform and k PCK1. l–p HepG2 cells were transfected with siRNA
targeting the first exon (1E) of HNF4α-P2 isoforms (n= 3), and RNA and protein was extracted at 48 h after transfection. qPCR of l HNF4α-P2 and
m HNF4α-P1. n Western blot of HNF4α-P1 and HNF4α-P2 in nuclear extracts. qPCR of HNF4α-P1 targets related to o metabolic functions (PCK1, ALB
and F7) and p bile acid synthesis and transport (BSEP, CYP7A1 and CYP27A1). q, r Primary human hepatocytes were silenced with siRNA-HNF4A-P2.
q Supernatant was collected 48 h after transfection (n= 3 for each group) and total bile acids were quantified. r Glucose production in P2-silenced primary
human hepatocytes. Significance was determined by unpaired, two-tailed Student’s t-test in a and c, by Fisher exact probability test in d, e and by two-
tailed Mann–Whitney U test in g, i, l, m, o, p, q, r: *P < 0.05. For box-and-whisker plots: perimeters, 25th–75th percentile; midline, median; individual data
points are represented
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treatment, RNA Pol II was found to be bound to a proximal
region of intron 1 that contains one FOS::JUN site. The same
region was also pulled down with the c-JUN antibody specially
under TGFβ1 treatment (Fig. 5j). These results indicate that
TGFβ1 promotes the recruitment of c-JUN and RNA Pol II to the
proximal intron 1 region. The effect of AREG on HNF4α-P1 was
blocked by the EGFR inhibitor PD15 (Supplementary Fig 9c). The
integrity of the MEK/ERK pathway was required for AREG-
mediated (Supplementary Fig. 9d) and TGFβ1-mediated (Sup-
plementary Fig. 9h, i) HNF4α-P1 downregulation. In contrast,
inhibition of c-Src did not restore HNF4α-P1 levels upon AREG
or EGF treatment (Supplementary Fig. 9e, f). Of note, for both
AREG and TGFβ1 to induce HNF4α-P1 downregulation, the
function of the proteasome must be intact (Fig. 5i and Supple-
mentary Fig. 9g), indicating a strong effect of these growth factors
in HNF4α-P1 protein stability. We then explored if the detri-
mental effect of TGFβ1 on hepatocyte function is mediated by
HNF4α-P2 increase. Transfection of primary human hepatocytes
and several cells lines (HepG2 and Hep3B cells) with siRNA
targeting P2 isoforms abolished TGFβ1-mediated suppression of
HNF4α-P1 (Fig. 5k–m, HepG2 experiments are shown). TGFβ1-
induced inhibition of HNF4α-P1 dependent genes, in particular
F7 and CYP7A1, was significantly reverted by P2 silencing while
the effect on other genes such as PCK1 or CYP27A1 was limited
(Fig. 5m, n, HepG2). The production of bile acids was similarly
restored by P2 silencing (Fig. 5o, primary human hepatocytes).
These results suggest that the re-expression of HNF4α fetal iso-
forms in AH could participate in TGFβ1-induced loss of hepa-
tocellular function, pointing to these isoforms as potential
therapeutic targets.
Next, we sought to identify potential mechanisms that
maintain the normal HNF4α P1/P2 ratio during the compen-
sated stages of ALD. Transcriptomic footprint analysis revealed
a marked predicted activation of PPARγ in early phases of ALD
(Fig. 2a). Interestingly, P2 silencing increased the expression of
PPARγ, indicating a potential antagonism with P2 (Fig. 6a).
Because of its hepatoprotective properties and its inhibitory
action on TGFβ137, we explored if PPARγ antagonizes TGFβ1-
mediated HNF4α dysregulation. The PPARγ agonist rosiglita-
zone increased P1 isoforms in all conditions and decreased the
abundance of P2 isoforms when TGFβ1 was combined with
AREG (Fig. 6b, c). TGFβ1-mediated ALB down-regulation was
restored by PPARγ activation. The effect of rosiglitazone on
HNF4α-P1 mRNA levels was dose dependent (Fig. 6d). Overall,
these results suggest that, in hepatocytes, PPARγ counteracts
TGFβ1-mediated HNF4α-P1 downregulation. This mechanism
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could partially explain the beneficial effects of PPARγ
agonists in experimental alcoholic and non-alcoholic liver
disease38.
miR122 is downregulated in patients with AH. HNF4α is the
main regulator of mir122 expression in hepatocytes through its
binding to the hpri-miR-122 promoter39. In our RNAseq analysis,
a number of patients with AH had low levels of liver miR122,
while other AH patients having normal levels (Fig. 7a). The fact
that HNF4α-P1 activity is suppressed in these patients suggests
that it could play a role in the decrease of miR122 expression.
Interestingly, some patients with early ASH had reduced levels of
miR122, indicating that alcohol itself could reduce miR122
expression. Patients with AH have increased levels of GRHL2
expression (Fig. 7b), a transcription factor that has been recently
associated with miR122 inhibition in a mouse model of ethanol
+ CCl4 mediated liver injury40. There was a significant inverse
correlation between these two genes (Fig. 7c). Whether this cor-
relation denotes causal relationship requires further investigation.
We used Ingenuity Pathway Analysis knowledge base to deter-
mine the significance (p value) and direction of the functional
enrichment (Z- Score) of all human miRNA of the set of differ-
entially expressed genes between early ASH and AH. Importantly,
miR122 was found to have the most significant negative Z-score
(Fig. 7d). HNF4α and miR122 dependent genes are only partially
overlapping (Fig. 7e), suggesting that miR122 dysfunction in the
c
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progression from early ASH to AH could involve HNF4α-inde-
pendent pathways. Finally, we used miRTarBase41, a curated
database of miRNA targets, to select the top 10 most validated
miR122 targets in humans. In patients with AH, 9 of those top
targets were upregulated while none of them was found increased
in early ASH (Fig. 7f). Although these new results support a
potential role for miR122 in AH, further functional experiments
are needed to confirm this hypothesis.
HNF4α-dependent genes are hypermethylated in AH patients.
Finally, we explored whether genetic or epigenetic factors are
Fig. 5 TGFβ1 induces the expression of HNF4α-P2 and binding by c-JUN to its promoter. a, b Immunoblots of HNF4α-P1 and HNF4α-P2 isoforms in Hep3B
cells treated with TGFβ1 and or AREG (50 nM) for a 12 and b 48 h (n= 2). c Immunoblots of HNF4α-P1 and HNF4α-P2 from Hep3B cells transfected with
an HNF4α-P1 specific siRNA for 48 h and treated with TGFβ1. d Hep3B cells were pre-treated with TGFβ-RI inhibitor SB431542 (5 nM) and treated with
TGFβ1 (for 8 h (n= 3); qPCR of HNF4α-P1 and P2, PCK1 and Ornithine Carbamoyltransferase (OCT). e SMAD4-silenced Hep3B cells were treated overnight
with TGFβ1; qPCR of SMAD4, HNF4α-P1 and P2 isoforms, PCK1 and OCT f Hep3B cells were pretreated with TAK1 inhibitor NG25 at 0.5 or 1 μM and then
treated with TGFβ1 for 8 h (n= 3). qPCR of HNF4α-P1 and P2 isoforms. g Hep3B cells were treated with TGFβ1 overnight in the presence of cellular Src (c-
Src) inhibitor PP2 (10 μM); g qPCR of HNF4α-P1 and P2 m Immunoblots of HNF4α-P1 and HNF4α-P2. k Chromatin immunoprecipitation of Hep3B cells
treated with TGFβ1 overnight; RNA Polymerase II (orange), phospho-c-JUN (red) antibodies and normal mouse IgG (blue) were used. qPCR of GAPDH
promoter, HNF4α-P2 promoter, and HNF4α-P2 proximal intron 1. Fold Enrichment of Pol II or c-JUN to control IgG is presented. l Hep3B cells were treated
with TGFβ1 for 24 h and with the addition of proteasome inhibitor MG132 (10 μM) 2 h before collection when indicated (n= 3); immunoblot of HNF4α-P1.
o–r HNF4α-P2-silenced HepG2 cells were collected 8 h (RNA) or 24 h (Nuclei) after TGFβ1 treatment (5 ng/ml) (n= 4–6); o qPCR of HNF4α-P2;
p immunoblot of nuclear HNF4α-P1 and P2 isoforms q qPCR of HNF4α-P1 target genes PCK1, ALB, F7 and r CYP7A1 and CYP27A1. s Primary human
hepatocytes were silenced with siRNA-HNF4α-P2 and supernatant was collected 48 h after transfection and 8 h after TGFβ1 treatment. Total bile acids in
supernatant were quantified (n= 3). Significance was determined by two-tailed Mann–Whitney U test in d, e, g, k, m, n, o *P < 0.05. For box-and-whisker
plots: perimeters, 25th–75th percentile; midline, median. The TGFβ1 dose used was 5 ng/ml
HNF4α-P1
HNF4α-P2
GAPDH
TGFβ1
AREG
ROSI
– + + – – + +
– – + – + – +
– – – + + + +
0.90 1.10 0.65 0.76 0.19 0.20 1.14 1.40 1.11 1.02 1.10 0.92 0.36 0.23
0.68 1.32 5.58 7.60 4.70 3.56 1.38 1.15 1.72 1.73 4.05 3.45 3.50 2.83
c
d
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
CTL
5
ROS
10
 
m
R
N
A 
(F
C)
HNF4α-P1
HNF4α-P2
*
*
0
2
4
6
0
1
2
3
0
1
2
H
N
F4
α
-
P1
 m
R
N
A 
(F
C)
H
N
F4
α
-
P2
 m
R
N
A 
(F
C)
AL
B 
m
R
N
A 
(F
C)
*
*
*
*
*
*
CT
L
RO
S
TG
Fβ1
RO
S+
TG
Fβ1 CTL RO
S
TG
Fβ1
RO
S+
TG
Fβ1 CTL RO
S
TG
Fβ1
RO
S+
TG
Fβ1
a
0
5
10
15
siS
CR
siH
NF
4A
-P
2
siS
CR
PP
AR
G
 
m
R
N
A 
(F
C)
b
TGFβ1
50
50
37
MWM
Fig. 6 PPARγ agonist Rosiglitazone partially restores TGFB1-induced HNF4A de-regulation. a HepG2 cells were transfected with HNF4α-P2 siRNA for 48 h
and collected 8 h after TGFβ1 treatment (5 ng/ml) (n= 5 for each condition);qPCR of PPARγ. b, c Hep3B cells were pretreated with rosiglitazone (10 μM)
overnight and then treated with TGFβ1 (5 ng/ml) and/or AREG (50 nM) for 8 h (n= 3 for each condition); b Immunoblot of HNF4α-P1 and HNF4α-P2
c qPCR of HNF4α-P1 and P2 isoforms and ALB. d Hep3B cells were treated with rosiglitazone at doses of 5 and 10 μM, and harvested 16 h after treatment;
qPCR of HNF4α-P1 and P2 isoforms (n= 3 for each condition). Significance was determined by two-tailed Mann–Whitney U test in a, b and d: *P < 0.05. For
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involved in the defective LETFs function in AH. To address this
question, we first analyzed GWAS data from a large cohort of AH
patients (N= 332) and patients with alcohol abuse that never
decompensated (N= 318) (Fig. 8a). None of the single nucleotide
polymorphisms (SNP) detected in LETFs including HNF4α,
either genotyped or imputed, were significantly associated with
AH development (Fig. 8b, c, Supplementary Data 3). Because
exposure to either TGFβ1 or alcohol have been involved in DNA
methylation and chromatin remodeling42–45, we hypothesize that
the disruption of the expression and activity of the transcriptional
master regulators (i.e LETFs) in patients with AH could be part of
a global epigenetic remodeling. In an unbiased fashion, we stu-
died the overall expression analysis of genes encoding epigenetic
modulators in patients with AH. For this purpose, we used the
EpiFactors database46. The top 5 hits of each family based on the
differential expression comparing normal and AH patients are
shown in Fig. 9a. Main genes found markedly deregulated
included HDAC 7, HDAC 11, PIWIL4 (MIWI2), NCOR2,
ZBTB33, PRDM6, PCGF2, and PHC2. The DNA methyl trans-
ferases 1 and 3 A were notably increased in patients with AH
(Fig. 9b, c). We then analyzed the methylation status of over
850,000 loci in normal livers (N= 5) and livers from AH patients
(N= 6) and found around 3000 differentially methylated (DM)
CpG-containing loci with an absolute change in beta value >0.3
and a false discovery ratio (FDR) <0.01 (Fig. 9d and Supple-
mentary Data 4). Motif enrichment analysis of DM regions
revealed the presence of HNF4α and PPARγ motifs in hyper-
methylated regions while hypomethylated regions were enriched
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Fig. 7 miR122 levels and miR122 predicted downregulation in AH patients. a RNA levels of hpri-miR122 in our cohort b levels of Grainyhead Like
Transcription Factor 2 (GRHL2) in our cohort c correlation of GRH2L2 and MIR122 levels. R and p value (Kendall) are presented. d Results of miRNA
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in motifs of inflammatory transcriptional regulators, such as
STAT4 and AP1 complex (c-FOS, JUN) (Fig. 9e). The analysis of
DM-CpG nearest genes with Ingenuity Pathway Analysis showed
that among hypermethylated regions HNF4α footprint was the
most enriched transcriptional regulator (Fig. 9f). These results
mirrored data from RNA-seq analysis, showing a parallel between
hypermethylation and down-regulation of regions controlled by
LETFs (eg. HNF4α, HNF1α, CEBPα, SREBPs, CEBPβ) and other
hepatoprotective factors such as PPARγ (Fig. 9f, g). These results
were confirmed by RNA-seq of the same samples (Fig. 9h). The
analysis of soluble upstream regulators revealed TNFα and
TGFβ1 involvement in the expression of genes containing
hypomethylated CpG (Fig. 9i). The presence of SNPs in differ-
entially methylated regulatory regions could be involved in dys-
regulation of the HNF4A locus or the HNF4α-dependent
transcriptome. Two annotated CpG islands near the HNF4A
locus were identified using the UCSC human genome browser,
which contained SNPs from the AH GWAS dataset (rs148377517
and rs13038786), although none of them were associated with the
risk of developing severe AH (OR of 0.62 and 1.89; P value of
0.3809 and 0.24, respectively). We then analyzed the SNP located
in Differentially Methylated Regions (DMR) located around the
HNF4A locus. Five DMRs around HNF4A locus were identified
and 20 SNPs fell within these DMR (Supplementary Data 5a, b).
Next, we analyzed the SNPs within or near HNF4α binding
motifs globally found within CpG islands and DMR. A total of
3214 DM CpG loci containing HNF4α binding motifs were
found. The SNPs lying±75bp from the locus of a DM CpG locus
were extracted from the AH GWAS dataset. In total 505 SNPs
fulfilled these criteria. Of these, 18 demonstrated a potential
association with the risk of developing AH (P < 0.05) (Supple-
mentary Data 5c). Of note, the SNP rs942043 lies near E2F3 gene
which encodes a transcription factor involved in cell cycle reg-
ulation. The variant rs846897 lies near the gene IGSF23, a
member of the immunoglobulin superfamily. Finally, we analyzed
the DMR around HNF4α binding motif-containing CpG loci. In
total, 328 DMRs were extracted and 36 SNPs were found in these
regions. Four variants, three of which were in perfect linkage
disequilibrium, demonstrated a potential association with disease
(P < 0.05) (Supplementary Data 5d). These lie within the coding
region of the gene CLCN6 that encodes a chloride transporter.
However, when viewed in the context of the number of tests
performed (SNPs found) these associations are highly likely to
represent false positives.
AH patients show repressive chromatin in HNF4α targets.
Finally, we analyzed data from H3K27Ac, H3K27me3, H3K4me1
and H3K4me3 chromatin immunoprecipitation experiments
coupled to DNA sequencing (ChIP-seq) of normal livers (N= 5)
and livers from patients with AH (N= 8) (Fig. 10a). H3K27Ac,
H3K4me1 and H3K4me3 marks are known to be enriched in
active regulatory regions, while H3K27 trimethylation results in
gene expression inhibition. As expected, in patients with AH, the
promoter regions of HNF4α targets such as PCK1, CYP3A4 and
F7 were poor in H3K27Ac, whereas other gene promoter targets
of ICAM1 were rich in this mark (Fig. 10b, c). When focusing on
the HNF4A genomic locus, we found enhanced H3K27Ac mark
in the P2 promoter, in accordance with our RNA expression
results (Fig. 10d). We then analyzed quantitatively the number
and significance of the peaks called in each sample. In clear
support of our findings in the RNA-seq cohort, patients with AH
had a decreased number and significance of H3K27Ac, H3K4me1
and H3K4me3 peaks in the HNF4A P1 promoter and increased
H3K27Ac enrichment in P2 promoter (Fig. 10e). A similar his-
tone modification pattern was found in the promoter of HNF4α
target genes such as PCK1 and CYP3A4. Interestingly, in F7
promoter, an increase in H3K4me3 was found (Fig. 10f). These
results suggest that the epigenetic regulation of HNF4α target
genes could be driven by different mechanisms. Other genes,
such as ICAM1 did not show differences on histone peak
fold enrichment (Fig. 10g). Further studies should identify
molecular drivers of methylation and chromatin remodeling in
AH, which could result in the development of novel targeted
therapies.
Finally, we explored whether the defective LETFs-dependent
gene expression in livers with AH results in an abnormal plasma
footprint of the corresponding proteins. We thus collected plasma
from controls (n= 15) and patients with AH (n= 10) and
performed mass spectrometry. Among the 288 plasma proteins
detected in plasma of both controls and AH patients (Supple-
mentary Fig. 11a), 60 corresponded to liver-secreted proteins
(Supplementary Fig. 11b) which gene expression was altered in
AH livers (Supplementary Fig. 11c). Importantly, 21 of these
proteins belong to the footprint of LETFs altered in AH
(Supplementary Fig. 11d) and correlated with changes in hepatic
gene expression (Supplementary Fig. 11e). Once validated in large
cohorts, these peripheral footprints could be useful for prognosis,
patient stratification or personalized treatment allocation in
future clinical trials.
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In conclusion, this human-based translational study found that
the development of hepatocellular failure in patients with AH is
characterized by a dramatic decrease in HNF4α-dependent gene
expression. The predicted decreased function was based on the
integrated analysis of main target genes. TGFβ1, a key upstream
transcriptome regulator in AH, induced the use of HNF4α P2
promoter in hepatocytes, which resulted in abnormal bile acid
synthesis and defective metabolic and synthetic functions. In a
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recent work analyzing human samples by IHC, the authors
describe a downregulation of HNF4α in patients with advanced
decompensated cirrhosis47. In our study, patients with compen-
sated cirrhosis and preserved synthetic function did not have a
functional HNF4α deficiency. It is therefore plausible that other
liver diseases characterized by decreased hepatocellular function
and liver-related complications are characterized by defective
HNF4α expression and/or function. Future analysis of transcrip-
tion factor activity in AH should include decompensated patients
as controls to better understand the specificity of these findings
and mechanisms of liver failure. Gene polymorphisms in LETFs
including HNF4α do not predispose to the development of AH,
while AH livers are characterized by profound changes in DNA
methylation state and chromatin remodeling in HNF4α-depen-
dent genes. The results of this study suggest that targeting TGFβ1
and epigenetic drivers that modulate HNF4α-dependent gene
expression could be beneficial in patients with AH.
Methods
Patients. For Human RNAseq studies, Human liver samples were obtained from
the Human Biorepository Core from the NIH-funded international InTeam con-
sortium (7U01AA021908-05). Patients with early alcoholic steatohepatitis (ASH)
were obtained from Cliniques Universitaires Saint-Luc (Brussels, Belgium). All
patients included gave written informed consent and the research protocols were
approved by the local Ethics Committees and by the central Institutional Review
Board of the University of North Carolina at Chapel Hill. A total of 79 patients
were included. Patients were selected according to different clinically relevant stage
groups: (1) patients with early ASH, who were non-obese with high alcohol intake,
and presented mild elevation of transaminases and histologic criteria of steatohe-
patitis (ASH, N= 12); (2) patients with histologically confirmed alcoholic hepatitis
(AH) who were biopsied before any treatment (AH, N= 18) and (3) explants from
patients with AH who underwent early transplantation following a well-defined
protocol48 (exAH, N= 11). These groups were compared with fragments of non-
diseased human livers (N= 10), patients with non-alcoholic fatty liver disease
(NAFLD) according to Keiner’s Crieria49 and without alcohol abuse (N= 9) and
from patients with non-cirrhotic HCV infection (N= 10) and compensated HCV-
related cirrhosis (N= 9). Patients with malignancies were excluded from the study.
Clinical characteristics of patients are described in Supplementary Table 1 and
depicted in Fig. 1c. A selection of liver samples from patients with AH (N= 6) and
fragments of normal human livers (N= 5), were used for Methylome and ChIP seq
analysis. For IHCs analyses, normal and AH liver samples were obtained at the
Division of Gastroenterology and Hepatology, Medical University of Graz, Austria.
All patients had clinically and histologically confirmed AH (N= 10) and did not
have any concomitant causes of chronic liver disease (N= 10)50. The study was
approved by the Ethics Committee of the Medical University of Graz and per-
formed in accordance with the Declaration of Helsinki, and all patients gave
written informed consent.
RNA extraction, sequencing and bioinformatic analysis. Total RNA from flash-
frozen liver tissue was extracted by phenol/chloroform separation (TRIzol, Ther-
mox). RNA purity and quality were assessed by automated electrophoresis
(Bioanalyzer, Agilent) and was sequenced using Illumina HiSeq2000 platform.
Libraries were built using TruSeq Stranded Total RNA Ribo-Zero GOLD (Illu-
mina). Sequencing was paired end (2 × 100 bp) and multiplexed. Ninety-four
paired-end sequenced samples obtained an average of 36.9 million total reads with
32.5 million (88%) mapped to GRCh37/hg19 human reference. Short read align-
ment was performed using STAR alignment algorithm with default parameters51.
To quantify expression from transcriptome mappings we employed RSEM52.
Principal component analysis (PCA) was done using made4 library53. Analysis of
differential expression was performed using the Limma package54. Cyclic loess
normalization was applied, followed by log transformation of the counts per
million and mean-variance adjustment using the voom function. The
Jonckheere–Terpstratest and Kendall correlation was used to check ordered dif-
ferences gene among progressive disease stages. To agglomerate gene patterns
along disease stages, Short Time-course Expression Miner (STEM) algorithm was
used through on-line platform55. The output of STEM analysis is shown in Fig. 1e,
f, Supplementary Fig. 2 and Supplementary Data 1. To uncover biological functions
related to gene expression changes, Gene Ontology (GO) enrichment through gene
set overlapping computation was done by means of rMATS, using the Canonical
Pathways (CP) collection, which includes 1329 gene sets56. To identify in an
unbiased way the transcription factors predicted to be directly involved on tran-
scriptomic changes we apply two methods: (1) Transcription factor motif searching
in gene promoters and proximal 5′ regulatory regions (±2000 bp from TSS) by
means of Opossum on-line tool57 and (2) Functional prediction of differentially
expressed genes (DEG) by the use of Ingenuity Pathway Analysis (IPA, Qiagen),
selecting among predicted upstream regulators, those involved in transcriptional
regulation (categories: “transcriptional regulator”, “ligand-dependent nuclear
receptor”). Only those hits found in both analyses were considered for the overlap.
A scheme of the methods used and a Venn diagram of the overlap between
Opossum and IPA outputs is shown in Supplementary Fig. 12. The statistic
approach used to calculate the predicted activation state (IPA) was Z Score (ZS)
and is used to infer likely activation states of upstream regulators based on com-
parison with a model that assigns random regulation directions. An overlap p‐value
to determine statistically significant overlap between the transcription factor target
gene dataset and the DEG for each comparison was also calculated using Fisher’s
Exact Test. For this study, the selected transcription factors (Figs. 2c, d, 5l and 9f)
showed an overlap p-value <0.01 for the comparison between Normal livers and
Early ASH and an overlap p-value <0.005 for the comparison between Early ASH
and AH. Opossum calculates two complementary scoring methods to measure the
over-representation of transcription factor binding sites: (1) Z-scores measures the
change in the relative number of TFBS motifs in the DEG gene set compared with
the background set, and (2) Fisher scores based on a one-tailed Fisher exact
probability assessing the number of genes with the TFBS motifs in the foreground
set vs. the background set. Since Opossum does not take into account the direction
of the expression changes, the top upregulated and the top downregulated genes
were scanned separately. Only those TF motifs with positive Z Score were con-
sidered. JASPAR database was used as the source of DNA binding profiles (Sup-
plementary Fig. 12).
HNF4α gene splicing analysis. RNA-seq reads were trimmed to a uniform length
of 75 bp using the FastxToolkit (http://hannonlab.cshl.edu/fastx_toolkit/). After
read trimming, alignment of RNA-seq reads was performed with the STAR aligner
(v2.5.2a) against the hg19 human genome. Resulting bam files were indexed with
samtools for rMATS58. Differential expression of splice isoforms was completed
using STAR alignment-StringTie-BallGown pipeline as described elsewhere59. To
identify exon-specific expression, an alternate pipeline was used. First, reads were
put through adapter trimming using TrimGalore (https://www.bioinformatics.
babraham.ac.uk/ projects/trim_galore/). After the trimming, reads were aligned
with the STAR aligner (v2.5.2a) against the hg19 genome. The resulting bam files
were then put through the DEXSeq R Bioconductor package (v1.26.0 for DEXSeq
and 3.3.1 for R) pipeline. To obtain raw read counts for each exon, we used a
standard DEXSeq script for exon counting (dexseq_count.py), with minor mod-
ifications. The exons were categorized in the GenCode v19 release. After exon
counting, individual R scripts were used to obtain the exon-specific expression
profiles. All custom scripts are available upon request.
Genomic DNA methylome analysis. Genomic DNA (gDNA) was extracted from
flash-frozen liver tissue with PureLink Genomic DNA Mini Kit (Thermo) and
quantified using Nanodrop (Thermo). In total 1 μg of isolated gDNA was bisulfite
converted, denatured, fragmented and hybridized to Infinium Methylation Bead
Chip, following the manufacturer protocol (Infinium MethylationEPIC kit, Illu-
mina). BeadChips were imaged using an Illumina Scan System and intensity was
determined by iScan Control Software (Illumina). Sample intensities were nor-
malized using functional normalization from the minfi package (v1.24.0)60. Probes
failing a detection p-value threshold (0.01) in at least 50% of samples were
removed, as were probes identified as containing a SNP with a MAF >0.05. Dif-
ferentially methylated probes were identified by applying limma (v3.34.3)54 con-
trasts to M values (absolute change in beta value >0.1, FDR-corrected P-value <
0.05). Differentially methylated regions were identified using DMRcate (v1.14.0)61
setting a threshold of absolute change in beta value in >0.1 and of Stouffer’s value
in <0.05.
Chromatin immunoprecipitation-PCR (ChIP-PCR). Hep3B cells were plated in
150 mm dishes at semi-confluence (106 cells/dish) in 10% DMEM media. TGFβ1
(5 ng/ml) was added to the media 24 h before the fixation of the cells. The chro-
matin preparation and immunoprecipitation was performed using EZ-ChIP kit
(Millipore, 17–371). Briefly, after treatment, cells were fixed with 1% formaldehide
(Sigma, F8775) for 10 min at room temperature. Quenching was performed with
125 mM glycine for 5 min. Cells were then washed twice with cold PBS and
scrapped in 1.8 ml of cold PBS containing Protease Inhibitor Cocktail per dish.
Cells were pelleted at low g and lysed with lysis buffer containing Protease Inhibitor
Cocktail. Chromatin sonication was performed using a Misonix 100W at 15% of
power by giving 6 pulses of 5 s with intervals of 30 s in ice, to obtain DNA
fragments between 200 and 800 bp. Each ml of sonicated chromatin contained the
equivalent of 10 million Hep3B cells. 100µL of sonicated chromatin was used in
each immunoprecipitation. Chromatin was then diluted to 1 ml with ChIP dilution
buffer and pre-cleared with Protein G-agarose for 1 h at 4 °C in continuous rota-
tion. Agarose pellet was then pelleted and discarded. A 10% of the sonicated,
precleared chromatin was removed and saved as INPUT. The rest of the chromatin
was immunoprecipitated using anti-RNA Polymerase II (Sigma-Aldrich, 05-623B,
1 μg) and anti-Phosho-c-JUN (Life, 711207, 5 μg), using normal mouse IgG as
control (Sigma-Aldrich, 12-371B, 1 μg), overnight at 4 °C in continuous rotation. In
total 60 μL of Protein G-agarose was then added and incubated for 1 h at 4 °C in
continuous rotation. The agarose beads were then pelleted and washed with Low
Salt Immune Complex Wash Buffer, High Salt Immune Complex Wash Buffer,
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LiCl Immune Complex Wash Buffer and TE Buffer (twice). DNA was eluted in
200 µL of elution buffer. The same buffer was also added to INPUT samples. For
reverse crosslinking samples, 8 mL 5M NaCl was added to each sample and eluates
were incubated for 5 h at 65 °C. Then, treatment with RNAse A (30 min at 37 °C)
and with Proteinase K (2 h at 45 °C) was performed. DNA was then purified using
spin columns, following manufacturer instructions. In order to avoid sonication
and immunoprecipitation batch effect, DNA from two different experiments was
pooled and aliquoted. The scanning of the genomic region around HNF4A-P2
Transcription Start Site (TSS), was performed by using JASPAR2018 Basic
Sequence Analysis62, selecting the matrix profiles for FOS:JUN heterodimer
(MA0099.2 and MA0099.3) and for JUN (MA0488.1). We found 6 binding sites
with high Relative Score (>85%) (Supplementary Fig 10). The oligonucleotides used
for the amplification of HNF4a-P2 promoter and intron regions and of control
GAPDH promoter can be found in Supplementary Table 2. Real time PCR was
performed in triplicate.
ChIP-seq of Histone marks. ChIP-seq was performed in Mayo Epigenomics
Development Laboratory (EDL)63. ChIP-seq with the liver tissue from 5 controls
and 7 severe AH explants (provided by University of Lille, France) were done for
four histone modifications, using antibodies against histone H3 Lysine 27 acet-
ylation (H3K27ac, Cell Signaling #8173), histone H3 Lysine 27 tri-methylation
(H3K27me3, Cell Signaling #9733), histone H3 Lysine 4 mono-methylation
(H3K4me1, EDL, Mayo Clinic, Lot#1) and histone H3 Lysine 4 tri-methylation
(H3K4me3, EDL, Mayo Clinic, Lot#1). For the next-generation sequencing, ChIP-
seq libraries were prepared from 10 ng of ChIP and input DNAs with the Ovation
Ultralow DR Multiplex system (NuGEN). The ChIP-seq libraries were sequenced
to 51 base pairs from both ends using the Illumina HiSeq 2000 in the Mayo Clinic
Medical Genomics Core. Data were analyzed by the HiChIP pipeline64. Briefly,
reads were aligned to the hg19 genome assembly using BWA and visualized using
the Integrative Genomics Viewer (IGV). Mapped reads were post-processed to
remove duplicates and pairs of reads mapping to multiple locations. The MACS2
and Sicer algorithm was used for peak-calling in relation to the input DNA. IGV
was then used to visualize H3K27ac peak changes on individual genes in this study.
Human primary hepatocytes and cell lines. Primary human hepatocytes were
purchased from Lonza. They were thawed in thawing medium (MCHT, Lonza),
plated in plating medium (MP, Lonza), and cultured in maintenance medium
(MM, Lonza). PHH were seeded on collagen-coated 12- or 6-well plates (Corning),
allowed to attach for 4 h, and then overlaid with Matrigel (0.3 mg/mL; Corning). In
silencing experiments, transfection was done 6 h before Matrigel overlay and cells
were kept in reduced serum media (OptiMEM, Gibco) during that time. Cells and/
or supernatant were collected at the indicated time points. HepG2 and Hep3B cells
were purchased from ATCC and were mycoplasma-free. They were expanded in
Dulbecco’s Minimum Essential Media (DMEM, Gibco) supplemented with 10%
Fetal Bovine Serum (FBS, Gibco), 1unit/mL Penicillin (Gibco), and 1 μg/mL
Streptomycin (Gibco). When indicated, cells were serum-starved (1% FBS DMEM)
2 h prior drug incubation. In silencing experiments, transfection was done 24 h or
48 h before treatment and cells were kept in OptiMEM for 6 h after transfection
and then in 1% FBS DMEM until harvesting. HepaRG cells were purchased from
ATCC and were mycoplasma free. They were incubated for 2 weeks in 2% DMSO
Williams E. HepaRG cells were grown in William’s E medium supplemented with
10% FBS, 100 U/mL penicillin, 100 μg/mL streptomycin, 5 μg/mL insulin, and
50 μM hydrocortisone hemisuccinate. After 2 weeks the medium was supple-
mented with 2% dimethyl sulfoxide (DMSO) and the cells were cultured for 2 more
weeks. For hepatocyte de-differentiation experiments, HepaRG cells were detached
and seeded at low confluence in the absence of DMSO65.
RNA extraction and Real Time Polymerase Chain Reaction. RNA from human
biopsies, for Real Time Polymerase Chain Reaction (RT-PCR) experiments was
extracted with Qiagen AllPrep DNA/RNA/Protein kit (Qiagen) following manu-
facturer’s instructions. For experiments with cell lines and primary hepatocytes,
RNA was extracted by phenol/chloroform method (TRIzol, Invitrogen). Con-
centration and purity was assessed by spectrophotometry (Nanodrop, Thermo). In
total 1 μg of total RNA was used for reverse transcription reaction using Maxima
First Strand cDNA Synthesis Kit for RT-qPCR with dsDNase (Thermo) following
manufacturer protocol. RT PCR of 50 ng of cDNA was performed in a 96 well
plate, using a CFX96 Real Time PCR detection system (BIO-RAD) and fluorescent
double-stranded DNA-binding dye (SsoAdvanced Universal Sybr Green Supermix,
BIO-RAD). Sequence of custom designed primers (Primer3 software) are in Sup-
plementary Table 2. The comparative CT method (2−ΔΔCt) was used to deter-
mine fold changes in mRNA expression compared a control group after
normalization to an endogenous reference gene (Ribosomal Protein L4, RPL4).
Protein extraction and Western Blot. Liver tissue fragments and cell pellets were
lysed in RIPA buffer (150 mM NaCl, 50 mM Tris pH 7.5, 0.1% SDS, 1% Triton X-
100) with the addition of 40 mM DTT, protease inhibitor cocktail (Complete,
Roche) and phosphatase inhibitors (1 mM Na3VO4, 2 mM NaF and 2 mM β-
glycerophosphate) just before protein extraction. For liver extracts, ratio 1:20 (mg:
μL) was used, and tissue was sonicated (5 cycles of 20 s with a 50W probe sonicator
at 20% Amplitude). In indicated cases, nuclear/cytoplasm fractionation was made
by using the NE-PER kit (Thermo), following the manufacturer protocol. For
western blot, 20–40 ug of protein extract was denatured with Laemli buffer
(AlfaAesar), boiled (95 °C for 3 min), loaded in SDS-PAGE system (BIO-RAD),
run until complete separation, transferred to a nitrocellulose membrane (0.2µm
pore diameter, BIO-RAD). Membranes were blocked for 1 h at room temperature
with 5% non-fat milk in 0.1% Tween20-Tris Buffered Saline (T-TBS). After
overnight incubation with primary antibodies (Supplementary Table 3), mem-
branes were washed three times with T-TBS and incubated with Near-Infrared
Florescent secondary antibodies (IRDye 680CW Goat anti-Rabbit and/or IRDye
800CW Goat anti-Mouse, LiCOR) for 1 h at room temperature and washed twice
with T-TBS and finally rinsed with TBS. Membranes were imaged using an Odissey
CLx Imager (LiCOR). For loading control of nuclear extracts, nitrocellulose
membrane was stained with REVERT Total Protein Stain (LiCOR). A repre-
sentative band was selected for western blot images in Figs. 2 and 3. Uncropped
blots can be seen in Supplementary Fig. 13.
Silencing of HNF4α isoforms P1 and P2 and of SMAD4. The sense-strand
sequences of the siRNAs were as follows: si-HNF4α-P1 (UUGAGAAU-
GUGCAGGUGUU-dTdT), si-HNF4α-P2 (GCTCCAGTGGAGAGTTCTT-dTdT)
and Scr (GCTGAGTAGAGTGTCCCTT-dTdT). SMAD4 siRNAs were purchased
from Life (Assay Id s8403 and s8405). The effective working concentration of
siRNA was 20pM in primary hepatocytes and 10pM in HepG2/Hep3B cells.
Transfection of siRNAs was performed by the use of Lipofectamine-RNAiMAX
(Invitrogen) following the manufacturer recommendations. This protocol showed
70–85% of silencing efficiency (mRNA and Protein level) at 24 and/or 48 h.
Overexpression of HNF4α isoforms P1 and P2. For overexpression of HNF4α-
P1 dependent isoforms, ORFs of human HNF4α2 and α8 isoforms were cloned in
pcDNA6 (Invitrogen) vectors under the CMV promoter. Plasmids were transfected
at the indicated doses in HepG2 cells using Lipofectamine 3000 (Invitrogen) fol-
lowing standard manufacturer protocol.
Cell culture treatments. TGFβ1 (5 ng/mL, R&D Systems) or amphiregulin
(AREG, 50 nM, Sigma Aldrich) were added immediately before Matrigel overlay
and mRNA or protein were collected at the indicated time points. For was used.
For proteasome inhibition, MG132 (10 μM, Calbiochem-EMD Millipore) was
added 45 min prior to cell harvesting. Treatments with TGF-β RI Kinase Inhibitor
VI (5 nM, SB431542, Calbiochem-EMD Millipore), TAKI Inhibitor (0.5 or 1 μM,
NG25 trihydrochloride, Axon), EGFR inhibitor (3 μM, PD153035, Calbiochem-
EMD Millipore), MEK Inhibitor (10 μM, UO126, Promega), c-SRC inhibitor
(10 μM,PP2, Calbiochem-EMD Millipore), Rosigiltazone (10 μM, Sigma) and were
performed after of 2 h starvation (1% FBS DMEM) and 45 min before TGFβ1
treatment.
Biliary acid quantification. Cryopreserved human primary hepatocytes (Lonza)
were plated overnight on collagen-coated 96-well plates at 2 × 104 cells per well in
MM (Lonza) and collected after 24 and 48 h of siRNA transfection. Total bile acids
were measured following the protocol supplied in the Total Bile Acid Assay Kit
available from Cell Biolabs (San Diego, Ca). Absorbance data was collected using
the SpectraMax M2 (Molecular Devices, Sunnyvale, CA, USA) microtiter plate
reader. The total bile acids were calculated by extrapolating test values to a cali-
bration curve as described in the assay kit. The levels of glycochenodeoxycholate
were measured by mass spectroscopy, as described elsewhere66. Briefly, 100 μL of
acetonitrile was added to 50 μL of cell culture. The samples were vigorously vor-
texed and then centrifuged (22,000 × g, 2.5 min). The supernatant fraction was
diluted 1:10 in 20% acetonitrile in H2O for analysis by LC–MS/MS. Glycocheno-
deoxycholate (Sigma) was used to prepare a standard curve (1 nM–10,000 nM).
The concentration of glycochenodeoxycholate in the media was determined by
linear regression analysis.
Glucose production assay. Cryopreserved human primary hepatocytes (Lonza)
were plated overnight on collagen-coated 12-well plates at 1 × 105 cells per well in
MM (Lonza). 24 h after plating, cells were serum-starved in DMEM base medium
(Sigma) supplemented with 1 g/L glucose (Sigma), 3.7 g/L sodium bicarbonate
(Sigma), and 4 mM L-glutamine (Corning) overnight, followed by 24 h incubation
in 0.3 ml glucose-production medium: DMEM base with 2 mM glutamine, 3.7 g/L
sodium bicarbonate, 15 mM HEPES (ThermoFisher), 20 mM lactate (Sigma),
2 mM pyruvate (Fisher) and 0.1 mM pCPT-cAMP (Sigma). After 24 h, 50 μL of
medium was removed for glucose detection with Invitrogen Glucose Colorimetric
Detection kit (#EIAGLUC), according to manufacturer’s protocol, and read on a
plate reader (Multiskan GO, Thermo-Scientific). Because hepatocytes were exten-
sively washed prior to cell incubation in glucose-free media for this assay, the only
potential source of glucose in the media is hepatic production. The prolonged
culture of cells in low glucose media prior to the assay depletes hepatocytes of
glycogen stores. The media used during this assay contains high concentrations of
gluconeogenic substrates, primarily lactate, favoring gluconeogenesis67,68.
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Model of alcoholic liver disease. Male mice (C57BL/6 J, 20–25 g, 12 weeks of age)
were obtained from the Jackson Laboratory (Bar Harbor, ME) and housed in a
temperature-controlled environment with a 12-h light-dark cycle and were given free
access to regular laboratory chow diet and water. All studies were approved by the
Institutional Animal Care and Use Committee at UNC-Chapel Hill. The model of
acute on chronic alcoholic liver injury in mice was performed as described else-
where69. CCl4 (>99.5% pure) and olive oil vehicle were from Sigma (St. Louis, MO),
ethyl alcohol (EtOH) (190 proof, Koptec) was from VWR (Radnor, PA). Procedures
for CCl4–induced liver fibrosis were as detailed elsewhere70. Mice were intra-
peritoneally injected (15ml/kg) with CCl4 (0.2 ml/kg) or olive oil vehicle-alone 2 ×
week for 6 weeks. After 6 weeks of CCl4 treatment, animals underwent surgical
intragastric intubation71. Following surgery, mice were housed in individual meta-
bolic cages and allowed 1 week to recover with ad libitum access to food and water.
Animals had free access to water and non-nutritious cellulose pellets throughout the
remaining study. Alcohol groups received high-fat diet containing ethyl alcohol as
detailed elsewhere71. Alcohol was delivered continuously through the intragastric
cannula initially at 16 g/kg/day and was gradually increased to 25 g/kg/day. All
animals were given humane care in compliance with the National Institutes of
Health guidelines and alcohol intoxication was assessed to evaluate the development
of tolerance. Experimental groups are detailed in the legend to Supplementary Fig. 4.
At the end of the study, mice were anesthetized with pentobarbital (50mg/kg, i.p.)
and sacrificed via exsanguination through the vena cava, which was the site of blood
collection. Tissues were excised and snap-frozen in liquid nitrogen.
Liver histopathological evaluation. Tissues were embedded in paraffin, sectioned
at 5 µm, and stained with hematoxylin and eosin (H&E) or Sirius red. For Oil red O
staining, tissues embedded in optimal cutting temperature compound were sec-
tioned at 10 µm. Liver pathology was evaluated in a blind manner by two inde-
pendent pathologists and scored as detailed elsewhere72. For Sirius red and oil red
O staining, quantitative analysis was performed using NIH ImageJ at 100 × mag-
nification in 5 random fields.
Immunohistochemistry. Dewaxed 3 µm thick sections were stained with hema-
toxylin and eosin (H&E) or chromatrope aniline blue (CAB) connective tissue stain
according to standard protocols. All slides were reviewed by a single pathologist
(CL). For immunohistochemistry paraffin sections were dewaxed and rehydrated.
Conditions of anti-human PPARγ, HNF1α, FOXA1 (HNF3α), RXRα, and HNF4α
(P1 and P2-isoforms) immunohistochemistry are summarized in Supplementary
Table 4. After immunohistochemical staining sections were counterstained with
hematoxylin (Labonord, Templemars, France) and mounted with Aquatex (Merck,
Darmstadt, Germany). Immunohistochemical signals were evaluated semi-
quantitatively by the application of numerical scores, based on the intensity of the
signal. For HNF4α, HNF1α and FOXA1, where the signal in AH patients was also
cytoplasmic, scoring was made separately for cytoplasmic and nuclear signals.
Single nucleotide polymorphism (SNP) cohorts. The AH exploratory study data
were obtained from a genome-wide association study of severe alcoholic hepatitis
published in abstract form73. Patients with AH were recruited through the steroids
or pentoxifylline for AH (STOPAH) trial74. Inclusion was based upon a clinical
diagnosis of alcoholic hepatitis, modified Maddrey’s discriminant (mDF) ≥ 32,
current excess alcohol consumption, recent onset of jaundice and exclusion of
other causes of decompensated liver disease. In order to reduce population
admixture only patients with self-reported “white” ethnicity were included. In
order to maximize phenotypic differences in the exploratory genome-wide asso-
ciation stage, in accordance with the study design, patients with biopsy-proven
disease and the most severe liver injury, as indicated by the mDF, were pre-
ferentially selected for inclusion in the exploratory cohort (n= 332). Controls with
a background of alcohol dependence but with no evidence of liver injury were
recruited via the University College London Consortium (n= 318). The majority
had been drinking hazardously for over 15 years and were actively drinking at the
time of enrollment and the absence of significant alcohol-related liver injury was
confirmed on liver biopsy. The remainder had no historical, clinical or radiological
features suggestive of significant liver injury either at presentation or during pro-
longed follow-up. All were of English, Scottish, Welsh or Irish descent with a
maximum of one grandparent of white European Caucasian origin. None of the
individuals was related.
SNP analysis. Samples were genotyped using the Illumina HumanCoreExome
beadchip at the Wellcome Trust Sanger Institute in Cambridge, UK. Quality
control and analysis of data were performed in PLINK v1.9075. Individual data
were quality controlled such that those with genotyping rate <98%, sample het-
erozygosity >3 standard deviations from the population mean, relatedness deter-
mined by pi-hat >0.185 or phenotypic and genotypic sex mismatch were excluded.
Markers with genotyping rate <98% or with a probability of deviation from Hardy-
Weinberg equilibrium <1 × 10-6 were also excluded. Population principal com-
ponents were calculated using a linkage-disequilibrium pruned data set of common
variants in PLINK v1.90, associations between principal components and case-
control status were tested in R. The resultant dataset was phased using ShapeIt v2.
r790 and imputed against the 1000 genomes project reference dataset using
IMPUTE v2.3.276. The imputed genotypes were hard-called using a probability
threshold of 0.9 and quality control filters were applied – missingness <5%, minor
allele frequency >1% and deviation from Hardy–Weinberg equilibrium <1 × 10−6.
Associations with case-control status were tested in PLINK v1.90 specifying the
principal components associated with case-control status as covariates. Only
autosomal data was analyzed. For the single marker analyses, key transcription
factors and related genes were identified through the primary analysis of RNAseq
data. Genomic coordinates for the coding regions of these genes, including 3′ and
5′ upstream regions, were obtained from Ensembl Biomart. Single nucleotide
polymorphisms (SNPs) falling within these genetic loci were extracted from the
AH study data. Analyses in the AH study data were limited to SNPs with a minor
allele frequency >1%. In order to control the false discovery rate a Bonferroni
correction was applied based upon 105 independent tests in the directly genotyped
dataset. Thus, the study-specific threshold for significance for tests of single SNPs
was 0.0005. For all other tests p < 0.05 was considered significant. For significantly
associated SNPs predicted effects on protein structure were predicted using SIFT77
and Polyphen78, expression quantitative train locus (eQTL) tests were conducted
using GTeX79. For gene- and pathway-based association tests were performed
using study summary statistics in MAGMA v1.0680 in accordance with recom-
mended procedures using reference files available at https://ctg.cncr.nl/software/
magma via the FUMA online server (http://fuma.ctglab.nl/,). Pathway-based
association testing was achieved by defining a biological pathway incorporating the
gene targets of interest.
Mass Spectrometry of plasma samples for proteomic analysis (LC–MS/MS).
Plasma samples from Control subjects (N= 10, 10 μL each) and plasma from
patients with AH (N= 15, 10 μL each) were pooled and protein concentration of
each group was determined by Qubit fluorometry. In total 10 μL of protein from
each pooled sample was depleted in duplicate on a Pierce™ Top 12 Abundant
Protein Depletion Spin Column (Thermo Scientific) according to manufacturer’s
protocol. Depleted samples were buffer exchanged into water on a centrifugal
concentrator (Spin X, Corning) using a 5 kD molecular weight cut off and quan-
tified by Qubit fluorometry (Life Technologies). 50 μg of each sample was reduced
with dithiothreitol, alkylated with iodoacetamide and digested overnight with
trypsin (Promega). The digestion was terminated with formic acid. Each digested
sample was processed by solid phase extraction using an Empore C18 (3M) plate
under vacuum (5in Hg). Briefly, columns were activated with 400 μL 95% acet-
onitrile/0.1% TFA X2, and then equilibrated with 400 μL 0.1% TFA X4. Acidified
samples were samples were loaded and columns were washed with 400 μL 0.1% TFA
X2. Peptides were eluted with 200 μL 70% acetonitrile/0.1% TFA X2 and then
lyophilized for further processing. 2 μg of each sample was analyzed by nano LC-
MS/MS with a NanoAcquity HPLC system (Waters) interfaced to a Q Exactive
(Thermo-Fisher). Peptides were loaded on a trapping column and eluted over a
75 μm analytical column at 350 nL/min using a 3 h reverse phase gradient. Columns
were packed with Luna C18 resin (Phenomenex). The mass spectrometer was
operated in data-dependent mode, with the Orbitrap operating at 60,000 FWHM
and 17,500 FWHM for MS and MS/MS respectively. The fifteen most abundant ions
were selected for MS/MS. Data were searched using a local copy of Mascot with the
following parameters: Enzyme: Trypsin/P; Database: SwissProt Human. Fixed
modification: Carbamidomethyl (C); Variable modifications: Oxidation (M), Acetyl
(N-term), Pyro-Glu (N-term Q), Deamidation (N/Q); Mass values: Monoisotopic;
Peptide Mass Tolerance: 10ppm; Fragment Mass Tolerance: 0.02 Da; Max Missed
Cleavages: 2. Mascot DAT files were parsed into Scaffold (Proteome Software) for
validation, filtering and to create a non-redundant list per sample. Data were filtered
using at 1% protein and peptide FDR and requiring at least two unique peptides per
protein. Normalized Spectral Abundance Factor (NSAF) values were used to obtain
the fold change between Normal and AH groups. For unbiased searching of secreted
protein coding genes from RNA-seq data, Retrieve/ID mapping on-line tool of
UniProt was used (filters “signal peptide” and “NOT transmembrane domain”)81.
Data availability
The RNA-sequencing and Methylomic raw data (Figs. 1, 2, 3a, 4, 7, 9 and Supplementary
Figs 2,3 and 5) have been deposited in the Database of Genotypes and Phenotypes
(dbGAP) of the National Center for Biotechnology Information (United States National
Library of Medicine, Bethesda, MD) under accession number phs001807.v1.p1. The
GWAS Summary used to generate Fig. 8 and Supplementary Data 3 and 5 and the ChIP-
seq peak calling data in Fig. 10 are publicly available (https://doi.org/10.5281/
zenodo.3233952).
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